A detailed history of Jane Street Group, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Jane Street Group, LLC holds 35,414 shares of VRDN stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,414
Previous 10,737 229.83%
Holding current value
$1.02 Million
Previous $150,000 407.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

BUY
$14.5 - $21.61 $357,816 - $533,269
24,677 Added 229.83%
35,414 $761,000
Q2 2025

Aug 14, 2025

SELL
$11.02 - $16.09 $710,227 - $1.04 Million
-64,449 Reduced 85.72%
10,737 $150,000
Q1 2025

May 14, 2025

BUY
$13.48 - $20.91 $366,170 - $567,999
27,164 Added 56.57%
75,186 $1.01 Million
Q4 2024

Feb 14, 2025

SELL
$17.85 - $25.71 $5.41 Million - $7.79 Million
-303,131 Reduced 86.32%
48,022 $920,000
Q3 2024

Nov 14, 2024

BUY
$12.16 - $23.33 $2.9 Million - $5.55 Million
238,078 Added 210.55%
351,153 $7.99 Million
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.26 $735,358 - $1.09 Million
63,393 Added 127.6%
113,075 $1.47 Million
Q1 2024

May 15, 2024

SELL
$17.09 - $23.82 $312,507 - $435,572
-18,286 Reduced 26.9%
49,682 $869,000
Q4 2023

Feb 14, 2024

BUY
$11.12 - $22.5 $92,651 - $187,470
8,332 Added 13.97%
67,968 $1.48 Million
Q3 2023

Nov 14, 2023

SELL
$15.16 - $24.7 $2.12 Million - $3.46 Million
-140,113 Reduced 70.14%
59,636 $914,000
Q2 2023

Aug 14, 2023

BUY
$22.57 - $29.67 $3.54 Million - $4.65 Million
156,704 Added 364.05%
199,749 $4.75 Million
Q1 2023

May 15, 2023

BUY
$25.04 - $37.6 $1.08 Million - $1.62 Million
43,045 New
43,045 $1.1 Million
Q2 2022

Aug 16, 2022

SELL
$9.55 - $19.0 $587,496 - $1.17 Million
-61,518 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$16.79 - $20.88 $1.03 Million - $1.28 Million
61,518 New
61,518 $1.14 Million

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $1.15B
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.